Keyphrases
Immunodominant Epitopes
100%
Vaccine Vector
100%
Rational Design
100%
AZD1222
100%
MHC Class II
44%
Viral Vectors
38%
Epitope
38%
Vaccine Platform
33%
Ad26
27%
T Cells
22%
ChAdOx1
22%
Ablating
22%
T Cell Immunity
16%
T Cell Response
16%
Immunopeptidome
16%
Pre-existing Immunity
16%
Adenovirus
16%
MRNA Vaccine
16%
Vaccination
16%
Cryogenic Electron Microscopy
16%
Viral Vaccines
16%
Virus
16%
Mass Production
11%
T Cell Epitope
11%
T Cell Recognition
11%
Viral
11%
HEK293 Cells
11%
CD8+ T Cells
11%
Exposed Population
11%
Anti-vector Immunity
11%
COVID-19 Pandemic
11%
Immunogenicity
11%
EM Model
11%
Plague
11%
Host Immunity
11%
Cell Response
11%
CD8+ T Cell Immunity
11%
ChAdOx1 Vaccine
11%
CoV-2
11%
CD8+ T
11%
Alternative Technology
5%
B Cells
5%
Mayo Clinic
5%
Epitope Prediction
5%
Targeted Therapeutics
5%
Rapid Response
5%
Variants of Concern
5%
Vector Development
5%
Emergency Setting
5%
Antigen-specific Immunity
5%
CD-8
5%
Antigen-specific T Cells
5%
New Targets
5%
Internal Medicine
5%
Engineering Skills
5%
Life Sciences
5%
Mutant Peptide
5%
Vaccine Response
5%
Past Success
5%
Co-immunoprecipitation (co-IP)
5%
Statistical Learning
5%
Structural Biology
5%
Immune System
5%
Ebola
5%
Functional Profile
5%
High Affinity
5%
Severe Disease
5%
Karen
5%
Cell Entry
5%
Adenovirus Infection
5%
Long-term Efficacy
5%
Adenovirus 26
5%
T Cell Activation
5%
Viral-vectored Vaccine
5%
Repeated Application
5%
Vaccine Candidate
5%
Shotgun Mass Spectrometry
5%
CanSino
5%
Molecular Modeling
5%
Deep Learning
5%
Dominant Epitopes
5%
SARS-CoV-2 Spike Protein
5%
Low Seroprevalence
5%
MD-PhD
5%
Adenoviral Vector
5%
Booster Vaccination
5%
Population Exposure
5%
Immune Response
5%
Cell Surface
5%
Arizona
5%
Molecular Science
5%
Cell-based
5%
Health Inequities
5%
Prediction Model
5%
Patient's Will
5%
Motivation
5%
Production Cost
5%
Vaccine Supply Chain
5%
B-cell Immune Response
5%
Structural Mapping
5%
Adenovirus Type 5
5%
Adenovirus Vector
5%
Adenovirus Vaccine
5%
Hexon
5%
Vector-based
5%
Immune Profiling
5%
Chimpanzee Adenovirus
5%
Immune Cell Interactions
5%
Target Antigen
5%
Storage Conditions
5%
Viral Vector Vaccine
5%
Seroprevalence
5%
Clinical Considerations
5%
B Cell Response
5%
Hypervariable
5%
Manufacturing Capacity
5%
Recombinant Adenovirus
5%
Ad26.COV2.S
5%
Therapeutic Benefits
5%
Therapeutic Vector
5%
Protein Engineering
5%
Novel Vaccines
5%
Mass Spectrometry
5%
Infection Reduction
5%
COVID-19 Vaccine
5%
Capsid
5%
Emergent Pathogen
5%
Mandatory Vaccines
5%
Pre-exposure
5%
Vector Engineering
5%
Delivery Vectors
5%
Immunobiology
5%
Storage Temperature
5%
Conventional Storage
5%
CD8+ T Cell Response
5%
NCoV-19
5%
Immunology and Microbiology
Vaccine Efficacy
100%
Epitope
100%
T Cell
54%
Major Histocompatibility Complex
36%
Viral Vector
36%
Cytotoxic T-Cell
31%
Adoptive Immunity
22%
Adenoviridae
18%
Vaccination Policy
18%
Cryo-Electron Microscopy
13%
B Cell
13%
Virus Vaccine
13%
Adenovirus Vector
13%
COVID-19
13%
Surface Property
9%
Immunogenicity
9%
Infectious Agent
9%
Immune Response
9%
Biochemistry, Genetics and Molecular Biology
T Cell
100%
Virus Vector
44%
Major Histocompatibility Complex
44%
CD8
44%
Cellular Immunity
27%
Adenoviridae
27%
Cryo-Electron Microscopy
16%
Messenger RNA
16%
B Cell
16%
Adenovirus Vector
16%
Surface Property
16%
Immunogenicity
11%
Immune Response
11%
Mass Spectrometry
11%
Infectious Agent
11%
Spike
5%
Antigen Specificity
5%
Cell Activation
5%
Protein Engineering
5%
Adaptive Immunity
5%
Human Adenovirus 5
5%
Seroprevalence
5%
Population Exposure
5%
Hypervariable
5%
SARS Coronavirus
5%
Storage Temperature
5%
Capsid
5%
Cell-Cell Interaction
5%
Immunoprecipitation
5%
Immunocompetent Cell
5%